Seattle Genetics Strengthens Pipeline with Acquisition of Cascadian for US$614 M
By Arun Manohar
Pharma Deals Review: Vol 2018 Issue 2 (Table of Contents)
Published: 10 Feb-2018
DOI: 10.3833/pdr.v2018.i2.2302 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Seattle Genetics has agreed to acquire Cascadian Therapeutics in a deal worth US$614 M to gain global rights to tucatinib (ONT-380), which is in Phase II clinical development for the treatment of metastatic human epidermal growth factor 2 positive (HER2+) breast cancer, and some early-stage oncology assets...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS